CN105377228B - 组合视黄醛和双甘氨肽油酰胺的化妆品或皮肤病学组合物及其化妆品或皮肤病学用途 - Google Patents
组合视黄醛和双甘氨肽油酰胺的化妆品或皮肤病学组合物及其化妆品或皮肤病学用途 Download PDFInfo
- Publication number
- CN105377228B CN105377228B CN201480039488.7A CN201480039488A CN105377228B CN 105377228 B CN105377228 B CN 105377228B CN 201480039488 A CN201480039488 A CN 201480039488A CN 105377228 B CN105377228 B CN 105377228B
- Authority
- CN
- China
- Prior art keywords
- skin
- retinene
- acid
- composition
- cosmetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 title claims abstract description 66
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 title claims abstract description 40
- 235000020945 retinal Nutrition 0.000 title claims abstract description 40
- 239000011604 retinal Substances 0.000 title claims abstract description 40
- 108010008488 Glycylglycine Proteins 0.000 title claims abstract description 33
- 229940043257 glycylglycine Drugs 0.000 title claims abstract description 33
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 title claims abstract description 32
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 239000002537 cosmetic Substances 0.000 title claims description 17
- 230000000699 topical effect Effects 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 47
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 32
- 235000019155 vitamin A Nutrition 0.000 claims description 18
- 239000011719 vitamin A Substances 0.000 claims description 18
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 16
- 229940045997 vitamin a Drugs 0.000 claims description 16
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 abstract description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 66
- -1 retinol ester Chemical class 0.000 description 22
- 239000002253 acid Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 229960003471 retinol Drugs 0.000 description 16
- 235000020944 retinol Nutrition 0.000 description 16
- 239000011607 retinol Substances 0.000 description 16
- 210000002615 epidermis Anatomy 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000011149 active material Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229930002330 retinoic acid Natural products 0.000 description 14
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical group C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 14
- 230000014509 gene expression Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 150000002148 esters Chemical class 0.000 description 12
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 12
- 229960001727 tretinoin Drugs 0.000 description 12
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 10
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 229920001971 elastomer Polymers 0.000 description 8
- 239000000806 elastomer Substances 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 5
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 5
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 5
- 102100032912 CD44 antigen Human genes 0.000 description 5
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 239000005642 Oleic acid Substances 0.000 description 5
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000010389 delta-tocopherol Nutrition 0.000 description 5
- 210000004207 dermis Anatomy 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 229940108325 retinyl palmitate Drugs 0.000 description 5
- 235000019172 retinyl palmitate Nutrition 0.000 description 5
- 239000011769 retinyl palmitate Substances 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 239000002446 δ-tocopherol Substances 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000021313 oleic acid Nutrition 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 102000004547 Glucosylceramidase Human genes 0.000 description 3
- 108010017544 Glucosylceramidase Proteins 0.000 description 3
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 3
- 240000006240 Linum usitatissimum Species 0.000 description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- UWNADWZGEHDQAB-UHFFFAOYSA-N 2,5-dimethylhexane Chemical group CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100033356 Lecithin retinol acyltransferase Human genes 0.000 description 2
- 235000021360 Myristic acid Nutrition 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102000000763 Survivin Human genes 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000013370 fibrillin Human genes 0.000 description 2
- 108060002895 fibrillin Proteins 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010084957 lecithin-retinol acyltransferase Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- IYIYMCASGKQOCZ-DJRRULDNSA-N motretinide Chemical compound CCNC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C IYIYMCASGKQOCZ-DJRRULDNSA-N 0.000 description 2
- 229960005406 motretinide Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Inorganic materials [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108090000064 retinoic acid receptors Proteins 0.000 description 2
- 102000003702 retinoic acid receptors Human genes 0.000 description 2
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229960000565 tazarotene Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- IKYKEVDKGZYRMQ-PDBXOOCHSA-N (9Z,12Z,15Z)-octadecatrien-1-ol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCO IKYKEVDKGZYRMQ-PDBXOOCHSA-N 0.000 description 1
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- PZBPKYOVPCNPJY-UHFFFAOYSA-N 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=C)CN1C=NC=C1 PZBPKYOVPCNPJY-UHFFFAOYSA-N 0.000 description 1
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
- BSLCSFCXSUCFQN-UHFFFAOYSA-N 1-aminobutane-2,3-diol Chemical compound CC(O)C(O)CN BSLCSFCXSUCFQN-UHFFFAOYSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- VULQAGPYFSUFCA-UHFFFAOYSA-N 16-methylheptadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CC(C)CCCCCCCCCCCCCCC(O)=O VULQAGPYFSUFCA-UHFFFAOYSA-N 0.000 description 1
- PNLVGFSEHLOUTK-UHFFFAOYSA-N 2-(bromomethyl)pentanedinitrile Chemical class BrCC(C#N)CCC#N PNLVGFSEHLOUTK-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- MPNXSZJPSVBLHP-UHFFFAOYSA-N 2-chloro-n-phenylpyridine-3-carboxamide Chemical compound ClC1=NC=CC=C1C(=O)NC1=CC=CC=C1 MPNXSZJPSVBLHP-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100031812 Fibulin-1 Human genes 0.000 description 1
- 101710170731 Fibulin-1 Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005795 Imazalil Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010024434 Lichen sclerosus Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- QHZLMUACJMDIAE-UHFFFAOYSA-N Palmitic acid monoglyceride Natural products CCCCCCCCCCCCCCCC(=O)OCC(O)CO QHZLMUACJMDIAE-UHFFFAOYSA-N 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101100203319 Schizosaccharomyces pombe (strain 972 / ATCC 24843) skh1 gene Proteins 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960005339 acitretin Drugs 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960002916 adapalene Drugs 0.000 description 1
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N alpha-glycerol monomyristate Natural products CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229920002892 amber Polymers 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 125000002511 behenyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960002206 bifonazole Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 150000007516 brønsted-lowry acids Chemical class 0.000 description 1
- 150000007528 brønsted-lowry bases Chemical class 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229960005074 butoconazole Drugs 0.000 description 1
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002125 enilconazole Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical class CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229960004849 isoconazole Drugs 0.000 description 1
- 229940100554 isononyl isononanoate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 108700019599 monomethylolglycine Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- XRRONFCBYFZWTM-UHFFFAOYSA-N octadecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(O)=O XRRONFCBYFZWTM-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960003483 oxiconazole Drugs 0.000 description 1
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940097411 palm acid Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 229920001192 peptidylglycine Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical class [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960002722 terbinafine Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 229940061629 trideceth-9 Drugs 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 235000021081 unsaturated fats Nutrition 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及基于视黄醛、双甘氨肽油酰胺、以及如有必要，δ‑生育酚‑吡喃葡萄糖苷的局部组合物，以及其在美容学和皮肤病学中对抗皮肤老化，更特别是光诱导的皮肤老化的用途。
Description
技术领域
本发明的目的是基于视黄醛和双甘氨肽油酰胺(d'oléamide deglycylglycine)，以及如有必要，δ-生育酚-吡喃葡萄糖苷的局部组合物，其在美容学和皮肤病学中的用途。
背景技术
皮肤的弹性和抵抗力归功于构成皮肤的不同组织层：表皮、真皮和皮下组织。表皮(皮肤的外层)负责皮肤的不透过性和抵抗力。其基本上由角蛋白(一种由角化细胞产生的纤维蛋白)和黑色素(由黑色素细胞生成的主要皮肤色素)组成。随着年龄增长，角化细胞的更新进行得更慢，并且其终末分化减慢。随着时间推移，在真皮发生深刻变化。一种支撑皮肤的组织，其包含80％的弹性纤维和嵌入糖蛋白凝胶中的胶原。成纤维细胞(其是真皮的主要细胞)专门进行这些弹性纤维和胶原的合成。在20至80岁间，成纤维细胞的数量减少一半。它们确保弹性纤维和胶原的合成、成熟和降解之间的平衡。随着时间推移，这种平衡会向着降解这些纤维的方向移动，结果是真皮弹性和张力的损失以及松弛，其不再对抗下方肌肉收缩的作用，导致皱纹的出现。胶原纤维分布在真皮的各层中，其能够结合水，并有助于皮肤的水合作用(hydratation)。胶原的减少和/或其质量的改变导致深皱纹的出现。随着年龄增长，给予组织弹性和坚实性的弹性纤维变得愈发稀少，皮肤变得更薄并形成皱纹。皮肤要不断地面对许多可能加速自然老化过程的外部侵袭。其对于来自自由基的攻击特别敏感，所述自由基通过我们身体的正常活动和外部元素(例如污染、烟草、和特别是太阳辐射)产生。这些自由基是导致皮肤老化的组织和细胞改变的原因。
维生素A(视黄醇)及其天然的和合成的衍生物(统称为类视黄醇)形成大量具有显著作用的各种物质，特别地在胚胎发育、生殖、视觉、生长、炎症、分化、增殖和细胞凋亡中具有显著作用。通过类视黄醇与RAR型核受体(视黄酸受体)和RXR型核受体(视黄酸X受体)的相互作用，介导类视黄醇的生物学效应。已知的RAR受体的配体是维生素A酸形式的反式异构体。
皮肤中含有大量的类视黄醇，以及参与其代谢的酶。类视黄醇是维生素A的天然或合成衍生物。比如天然类视黄醇，可以提及视黄醇及其所有的代谢衍生物、视黄醛、全反式视黄酸、9-顺式-视黄酸、13-顺式-视黄酸及其酯(例如棕榈酸视黄酯)。合成类视黄醇是其中一部分已被修饰的分子，目的是为了使化合物具有与维生素A相关的单种作用。主要的分子有依曲替酯、阿维A酸、他扎罗汀、阿达帕林、贝沙罗汀、莫维A胺(motrétinide)。
人的表皮中含有维生素A的两种主要形式，视黄醇和视黄酯(esters rétinyliques)。通过将视黄醇酯化为视黄酯，将维生素A储存于角化细胞中。该步骤由两种酶催化，酰基辅酶A酰基转移酶和卵磷脂视黄醇酰基转移酶。它们的表达受到UV幅射和角化细胞的分化状态的调控。通过视黄酯水解酶催化视黄酯向视黄醇的水解。另一方面，视黄醇是视黄酸的激素原，其被氧化为视黄醛，视黄醛自身被氧化为视黄酸(维生素A的一种生物活性形式)。鉴于视黄酯在表皮中且主要在角质层中的浓度比在真皮中或进一步地在血液中更高，而且其是维生素A的其他活性形式的前体，因此视黄酯被认为是维生素A的储存形式。类视黄醇(含有多不饱和脂链)的化学性质及其物理特性(赋予其在320至390nm之间的最大吸收)使其能够与UV或与氧相互作用，以产生氧的活性形式或自由基。其可以通过UV异构化。然而在大多数情况中，在UV的作用下类视黄醇完全被破坏。似乎视黄酯比视黄醇更敏感。暴露于日光下的表皮比未暴露的皮肤含有更少的视黄酯，这表明UV诱导维生素A的缺乏(Sorg等人,Dermatology,199(4):302–307,1999)。这个和其它观察结果都支持以下假设：由日光诱导的维生素A的损耗(déplétion)牵涉到某些皮肤癌以及过早老化的发病机制(Sorg等人,Dermatol.Ther.,19(5):289–296,2006)。可以通过维生素A的外部补充弥补这种损耗。
已知局部应用类视黄醇用于向皮肤补充维生素A。此外，已知在局部应用期间，类视黄醇的主要副作用之一仍然是诱导的刺激。这种作用可能严重阻碍(rédhibitoire)治疗的遵守。
局部视黄醇发挥类似的生物作用，但与局部视黄酸的那些作用相比不那么强烈，但有较小的刺激，通过将视黄醇转化为视黄酸介导这些反应。视黄醇及其酯必须被转化为视黄酸以在人角化细胞中诱导生物作用。以相同的方式，被转化为储存形式(视黄酯)或活性形式(视黄酸)的视黄醛发挥显著的生物活性，并且其比视黄酸耐受性更好(Saurat等人,J.Invest.Dermatol.,103:770–774,1994)。其也是用于在表皮中补充维生素A的良好候选物。已证明通过诱导表皮增生，以及在C57BL/6和无毛SKH1小鼠(无毛小鼠)的滤泡(folliculaire)和滤泡间(interfolliculaire)表皮中CD44和透明质酸表达的显著增加，视黄醛在皮肤中发挥生物活性。在局部应用视黄酸和视黄醇之后也观察到这些作用。然而在用视黄醛处理的小鼠中，CD44和透明质酸的表达增长得更强。CD44是一种多态跨膜糖蛋白，其具有由可变剪接和翻译后变化而产生的数种异构体。已证明在鼠科动物皮肤中CD44的两种主要功能为1)响应细胞外刺激调节角化细胞增殖和2)维持透明质酸的局部平衡(Kaya等人,Genes&Development,11(8):996–1007,1997)。在患有硬化性苔藓(lichen scléro-atrophique)的患者中也观察到表皮CD44表达的降低，其可能是这种疾病中的透明质酸的真皮沉积和表皮萎缩的原因(Kaya等人,J.Invest.Dermatol.,115(6):1054–1058,2000)。
根据皮肤病学中的两种策略实现类视黄醇的应用：
-在治疗皮肤病理学的情况中的药理剂量下，视黄酸的应用(0.025％至0.1％的凝胶或霜剂)具有治疗痤疮的主要适应症。其还用于治疗光老化和日光性角化症。他扎罗汀被用于治疗银屑病(0.05％至0.1％的凝胶)。对于莫维A胺(0.1％霜剂或洗剂)，其被用于治疗轻度痤疮。
-对于化妆品目的：棕榈酸视黄酯(0.5％至5％的凝胶)、视黄醇(0.1％至0.6％)和视黄醛(0.05％)被用于抗老化治疗和恢复性护理。
太阳辐射包括可见光、紫外线(UV)、红外线和其他电磁辐射。正如可见光可以被分开为多种颜色，以同样的方式也可以将UV分类为三个分支：
-UVA(315-400nm)代表到达地球表面的UV的主要部分。它们导致皮肤晒黑，并且因为它们容易穿透组织，所以可能会深度损伤皮肤。
-UVB(280–315nm)代表到达地面的射线的小得多的部分，但是对于日光暴露的连续生物作用具有显著的贡献。它们可能引起发红、灼伤、晒黑、眼部损伤。它们对皮肤的穿透较低。
-UVC(200–280nm)几乎完全被大气的臭氧层吸收。它们只是非常轻微地穿透皮肤，但是可能引起眼部损伤。
UV对皮肤的主要作用是红斑、光衰老、皮肤癌。在暴露于UV后，在表皮和真皮中金属蛋白酶的表达增加。这些改变真皮中胶原的产生的酶有助于皱纹的出现。通过反复暴露维持这些酶的诱导(Fisher等人,N.Engl.J.Med.,337:1419–1428,1997)。由于弹性材料的积累导致真皮加厚。UV照射后表皮产生的白细胞介素有助于结缔组织的破坏。似乎在真皮中观察到的作用可能归因于UVA，不同于UVB其穿透很远的距离。在无毛小鼠中，像在人中一样，在用UVB长期照射后观察到增生和皱纹的出现，并且皮肤在UVA的作用下变得松弛。所观察到的作用取决于照射的波长。在用295至300nm之间的波长照射后，真皮变得更厚，胶原纤维被破坏并产生异常弹性纤维，这被称为弹性组织变性。在用UVA照射10周之后，不再有任何正常的弹性纤维。
许多研究已经允许建立起慢性日光暴露和发展为皮肤癌的倾向之间的联系。进一步地，UV改变某些基因例如p53，该基因负责在DNA水平去除或修复损伤。UVB和UVA对人类细胞免疫的作用并不相同。UVA致癌性较弱。因此，UVB在日光暴露的致癌作用中发挥主导作用。色素沉积是对UV的基本敏感性中涉及的要素。被黑色素细胞的黑色素吸收的UVA将成为皮肤癌的起源。事实上，UVA是黑素瘤的发生的原因，但是UVB也是其发展直至转移的原因。
视黄醛和视黄酸的主要适应症为光损伤(héliodermie)的治疗，其对应于常常过早的、由慢性和/或长时间暴露于日光下而产生的皮肤老化。损伤直接取决于所接受的剂量。
下式的双甘氨肽油酰胺：
CH3–(CH2)7–CH＝CH–(CH2)7–CO–NH–CH2–CO–NH–CH2–COOH是一种来自油酸和双甘氨肽二肽的缩合的脂肽或酰基肽。
双甘氨肽油酰胺因其在液体洗涤剂组合物中的表面活性剂性能而被知晓(US4732690和JP 5984994)。专利EP 1061897的目的是双甘氨肽油酰胺用于制备组合物的用途，所述组合物旨在更一般地通过刺激细胞代谢，对抗结缔组织的蛋白纤维的糖化和弹性组织变性。
在自然状态下，在许多植物中，α-生育酚或维生素E通常与其他化合物如β-生育酚、γ-生育酚或δ-生育酚一起被发现。α-生育酚主要用于对抗维生素E缺乏，或者作为营养因子，特别地用于对抗肌肉退化。在非常特定的剂量，其还被用作抗氧化剂。含有这些生育酚的美容组合物已经是市售可得的。然而，已证明在温和的氧化条件下，这些抗氧化剂在皮肤上的直接应用导致促炎症作用，所述促炎症作用是在常用浓度下过度活跃(suractivité)的结果。因此，这些生育酚中的许多结构性改变已经给出了限制副作用的可能性，允许它们用于治疗或预防皮肤的其它疾病或病症。因此，WO 98/51679公开了在化妆品或药物组合物中的生育酚酯。在国际申请中描述了这些生育酚酯是抗自由基、抗炎、促进角化细胞的分化、改善皮肤水合作用和皮肤纹理的光滑度、用于预防或治疗皮肤老化作用、具有亮肤活性或对神经末梢的麻醉作用。专利EP 1062223描述了在美容学或皮肤病学中，更特别地在皮肤疾病(特应性皮炎、痤疮、银屑病)的治疗中的活性物质的前体。该发明的主题涉及葡糖脑苷脂酶的用途，所述葡糖脑苷脂酶是一种存在于所有细胞中的溶酶体酶，且因此天然存在于皮肤中。葡糖脑苷脂酶水解活性前体，从而释放生物活性物质。通过这种手段，减少甚至抑制了副作用。该专利还公开了δ-生育酚的碳水化合物前体的用途，以及更特别地δ-生育酚-吡喃葡萄糖苷的物理化学特性和生物特性。δ-生育酚-吡喃葡萄糖苷被葡糖脑苷脂酶酶促水解缓慢释放δ-生育酚，其具有比参考衍生物(4-甲基伞花基吡喃葡萄糖苷(4-méthylumbelliféryl glucopyranoside))更低的动力学。这种缓慢释放提供了避免δ-生育酚活性物质过度集中的可能性，因此提供了避免产品应用过程中的任何炎症作用的可能性。因此，活性物质的缓慢释放确保其在皮肤介质中更好的生物利用度，并因此确保更有效的保护。特别地在EP 1062223中，公开了葡萄糖轭合物(glucoconjugués)与游离活性物质相比的极低的活性：特别地，相比于δ-生育酚，δ-生育酚-吡喃葡萄糖苷具有弱抗氧化潜力。
由申请人进行的研究提供了揭示视黄醛和双甘氨肽油酰胺的组合对角化细胞中类视黄醇代谢的协同作用的可能性。
出人意料地，与视黄醛和双甘氨肽油酰胺相组合的δ-生育酚-吡喃葡萄糖苷具有对整个真皮的皮肤病学活性，揭示了对抗皮肤老化，更特别地对抗光诱导的皮肤老化的非常显著的作用。因此，三种活性物质的组合对许多基因具有非常广谱的作用，在光诱导老化期间所述基因的表达被改变。
发明内容
本发明的目的涉及包含视黄醛和双甘氨肽油酰胺作为主要成分的化妆品或皮肤病学组合物。
本发明的目的还涉及包含视黄醛和双甘氨肽油酰胺作为活性成分，以及至少一种化妆品或皮肤病学上可接受的载体的化妆品或皮肤病学组合物。
根据另一个实施方案，所述组合物包含视黄醛、双甘氨肽油酰胺和δ-生育酚-吡喃葡萄糖苷作为活性成分，以及至少一种化妆品或皮肤病学上可接受的载体。
根据一个优选的实施方案，赋形剂以旨在用于局部应用的形式出现。本发明的目的最特别地为在被视为脆弱的皮肤区域的局部应用，所述皮肤区域例如面部、颈部、眼睛的周围和嘴唇的周围。
“载体”意指允许制造、保存和施用化妆品或皮肤病学组合物的任何佐剂或赋形剂。在根据本发明的组合物中可以使用在化妆品或皮肤病学观点上可接受的任何载体，例如选自常用于盖伦(galénique)混合物中的赋形剂。
有利地，根据本发明的组合物含有基于组合物总重量以重量计0.01至1％的视黄醛，优选以重量计0.015至0.1％的视黄醛。
根据本发明一个优选的实施方案，所述组合物含有基于组合物总重量以重量计0.015％的视黄醛。
根据本发明另一个优选的实施方案，所述组合物含有基于组合物总重量以重量计0.05％的视黄醛。
根据本发明又一个优选的实施方案，所述组合物含有基于组合物总重量以重量计0.1％的视黄醛。
有利地，根据本发明的组合物含有基于组合物总重量以重量计0.0001至20％的双甘氨肽油酰胺，优选以重量计0.001至10％的双甘氨肽油酰胺，优选以重量计0.01至1％的双甘氨肽油酰胺，更有利地以重量计0.05至0.5％的双甘氨肽油酰胺。
根据本发明一个优选的实施方案，所述组合物含有基于组合物总重量以重量计0.1％的双甘氨肽油酰胺。
有利地，根据本发明的组合物含有基于组合物总重量以重量计0.001至10％的δ-生育酚-吡喃葡萄糖苷，优选以重量计0.01至5％的δ-生育酚-吡喃葡萄糖苷，优选以重量计0.05至0.5％的δ-生育酚-吡喃葡萄糖苷，更有利地以重量计0.05至0.15％的δ-生育酚-吡喃葡萄糖苷。
根据本发明一个优选的实施方案，所述组合物含有基于组合物总重量以重量计0.05至0.1％的δ-生育酚-吡喃葡萄糖苷。
根据本发明优选的实施方案，根据本发明的组合物含有基于组合物总重量0.01至0.1％的视黄醛，0.1％的双甘氨肽油酰胺以及0.05至0.1％的δ-生育酚-吡喃葡萄糖苷。
根据本发明的组合物可以作为水包油(H/E)乳剂或油包水(E/H)乳剂出现。其还可以作为球剂(sphérules)(例如脂质体、纳米胶囊或纳米球)出现。
可以在本发明中使用的油相为：
‐固体或糊状脂肪相，例如蜂蜡、小烛树蜡、巴西棕榈蜡、石油蜡(或微晶蜡)、石蜡；及其混合物；
‐动物源和/或植物源的油；及其混合物；
‐具有8个以上碳原子的、直链或支链的、饱和或不饱和的合成来源的烃油，例如氢化聚异丁烯(Parleam油)、石蜡油(或凡士林，或液体石蜡)、异链石蜡、柠檬烯、角鲨烯、聚异丁烯或异辛烷；及其混合物；
‐由较高级的脂肪酸形成的油，所述脂肪酸尤其为C10-C22脂肪酸，例如肉豆蔻酸、棕榈酸、硬脂酸、山嵛酸、油酸、亚油酸、亚麻酸或异硬脂酸；
‐由较高级的脂肪醇形成的油，所述脂肪醇尤其为C10-C22醇，例如油醇、亚油醇或亚麻醇、异硬脂醇或辛基十二醇；及其混合物；
‐由直链或支链的、饱和或不饱和的式RCOOR’的酯形成的油，其中R代表包含7至19个碳原子的较高级的脂肪酸的剩余部分，且R’代表包含3至20个碳原子的烃链，所述式RCOOR’特别地为C12-C36酯，例如肉豆蔻酸异丙酯、棕榈酸异丙酯、硬脂酸丁酯、月桂酸己酯、己二酸二异丙酯、异壬酸异壬酯、2-乙基-己基棕榈酸酯、2-己基-癸基月桂酸酯、2-辛基癸基棕榈酸酯、2-辛基十二烷基肉豆蔻酸酯或2-辛基十二烷基乳酸酯、二(2-乙基-己基)琥珀酸酯、苹果酸二异硬脂醇酯、羟基硬脂酸异硬脂醇酯、羟基硬脂酸乙基己基酯、乙基己酸鲸蜡硬脂醇酯、异硬脂酸异硬脂醇酯；及其混合物；
‐由C1-C30羧酸的甘油单酯、C1-C30羧酸的甘油二酯、C1-C30羧酸的甘油三酯形成的油，所述甘油单酯、甘油二酯、甘油三酯例如辛酸甘油单酯、辛酸甘油二酯或辛酸甘油三酯，和癸酸甘油单酯、癸酸甘油二酯或癸酸甘油三酯、棕榈酸甘油单酯、棕榈酸甘油二脂和棕榈酸甘油三酯、亚油酸甘油单酯、亚油酸甘油二酯和亚油酸甘油三酯、硬脂酸甘油单酯、硬脂酸甘油二脂和硬脂酸甘油三酯、异硬脂酸甘油单酯、异硬脂酸甘油二酯和异硬脂酸甘油三酯、山嵛酸甘油单酯、山嵛酸甘油二酯和山嵛酸甘油三酯、油酸甘油单酯、油酸甘油二酯和油酸甘油三酯、肉豆蔻酸甘油单酯、肉豆蔻酸甘油二酯和肉豆蔻酸甘油三酯、亚麻酸甘油单酯、亚麻酸甘油二酯和亚麻酸甘油三酯；及其混合物；
‐非挥发性硅油，例如非挥发性聚二甲基硅氧烷(PDMS)；改性聚硅氧烷；胺化硅酮，或具有羟基的硅酮，或氟化硅酮；二甲聚硅氧烷；三甲聚硅氧烷；及其混合物。优选地，可以在本发明范围内使用的二甲聚硅氧烷可以以商标名(General ElectricCompany)、DOW CORNING(Dow Corning Corporation,DC200)、DOW CORNING获得，或者本领域技术人员已知的任何其他脂肪相。
所述组合物还可以包含用于调节皮肤的试剂。皮肤的调节剂的示例包括但不限于阴离子型、阳离子型、非离子型乳化剂，例如月桂基硫酸钠、磺基琥珀酸二辛酯钠、硬脂酸钠、山梨聚糖酯、乙氧基化脂肪酸、乙氧基化脂肪醇、十三烷醇聚醚-9和PEG-5己酸乙酯，以及本领域技术人员已知的任何乳化剂和调节剂。
对于具有醇-水或醇基的根据本发明的组合物，任何单醇的使用是合适的。
所述组合物可以进一步包含在室温(25℃)可与水混溶的多元醇，所述多元醇尤其选自特别地具有2至20个碳原子，优选具有2至10个碳原子，且优选具有2至6个碳原子的多元醇，例如甘油、乙二醇衍生物例如丙二醇、丁二醇、戊二醇、己二醇、二丙二醇、二甘醇；乙二醇醚例如单、二或三-丙二醇(C1-C4)烷基醚，单、二或三-乙二醇(C1-C4)烷基醚；及其混合物。
所述组合物可以进一步包含抗菌剂，例如选自可以包含一个或多个芳香取代基的醇的防腐剂或抗真菌剂，例如苯氧乙醇(如2-苯氧乙醇)、1-苯氧基-2-丙醇、苄基醇、2-羟基联苯、咪唑烷基脲、重氮烷基脲、羟甲基甘氨酸钠、卤化衍生物例如碘丙炔基丁基氨基甲酸酯、2-溴-2-硝基丙-1,3-二醇、2,4,4’-三氯-2’-羟基联苯醚(三氯生)、3,4,4’-三氯碳酰替苯胺(三氯卡班)、chlorbutanulum、2,4-二氯苄醇、N-4-氯苯基-N’-3,4-二氯苯基脲、1,2-二溴-2,4-二氰基丁烷、氯二甲苯酚、酮康唑、奥昔康唑、布康唑、克霉唑、益康唑、恩康唑、芬替康唑、咪康唑、硫康唑、噻康唑、氟康唑、伊曲康唑、特康唑、包含一个或多个阳离子氮原子的活性物质例如十六烷基三甲基氯化铵、氯化十六烷基吡啶、苄索氯铵、二异丁基乙氧基乙基-二甲基苄基氯化铵、二异丁基-苯氧基-乙氧基乙基-二甲基苄基氯化铵、N-烷基-N,N-二甲基苄基氯化铵、溴化糖精、三甲基氯化铵、氯羟基乙酸钠铝(aluminiumchlorohydroxylacétate de sodium)、三(十六烷基)甲基氯化铵、二氨基烷基酰胺、有机酸及其盐例如柠檬酸、不饱和抗菌剂例如法呢醇、特比萘芬或萘替芬、杂环芳香试剂例如联苯苄唑、氯康唑(cloconazole)、异康唑，以及本领域技术人员已知的任何其他抗细菌或抗真菌剂及其混合物。
所述组合物还可以包含增稠剂或改变流变性的试剂如，例如疏水改性的乙氧基化非离子型氨基甲酸乙酯、聚羧酸增稠剂例如丙烯酸酯/硬脂醇聚醚-20甲基丙烯酸酯共聚物、卡波姆、丙烯酸酯共聚物和丙烯酸酯以及交联C10-C30烷基丙烯酸酯；及其混合物。
所述组合物还可以包含允许调节所述组合物的pH范围的酸和碱。所述碱可以为无机的(苏打、苛性钾、氨)或有机的例如单、二或三乙醇胺、氨甲基丙二醇、N-甲基-葡糖胺、碱性氨基酸如精氨酸和赖氨酸；及其混合物。
所述组合物可以进一步包含一种或多种其他成分，例如pH缓冲剂、维生素、芳香剂、以及本领域技术人员熟知的任何其他有用的化合物。
根据本发明的组合物可以被规定为软膏、喷雾剂、洗剂、凝胶、泡沫剂、分散剂、浆液(sérum)、面膜、身体乳或霜。
根据本发明的组合物可以用于美容学和皮肤病学中，用于预防或改善有皱纹的皮肤，并且提供保持皮肤的紧实度和湿度的可能性。
根据本发明的组合物可以用于皮肤病学或美容术学领域的局部制剂中，目的在于预防和/或减少皱纹，对抗无论是否是由光诱导的皮肤老化，重新激发表皮和真皮细胞的活性，紧致皮肤，增加其弹性，增加皮肤中维生素A的生理储备。
本发明还涉及根据本发明的组合物用于对抗皮肤老化，更特别地对抗光诱导的皮肤老化的化妆品用途。
本发明还涉及根据本发明的组合物用于增加皮肤中维生素A的生理储备的化妆品用途。
本发明还涉及一种用于对抗光诱导的皮肤老化的美容方法，其包括在皮肤上应用根据本发明的组合物。
本发明还涉及一种用于增加皮肤中维生素A的生理储备的美容方法，其包括在皮肤上应用根据本发明的组合物。
本发明还涉及根据本发明的组合物，其用作用于治疗与皮肤中维生素A生理储备的缺乏有关的皮肤病变的皮肤病学药物。
通过以下实施例以非限制性方式阐明本发明。
具体实施方式
实施例1
通过使用局部类视黄醇的预处理预防由UV幅射诱导的损耗(Tran等人,Photochem.Photobiol.73(4):425–431,2001)。
在无毛小鼠中进行该研究。以0.05％局部应用类视黄醇持续7天，然后提供UVB幅射(1J/cm2)。在幅射后24h测试表皮的类视黄醇。
结果示于图1，其具有标题：通过使用局部类视黄醇的预处理预防UV诱导的损耗。
通过用类视黄醇装载表皮，视黄醛和视黄醇预防光诱导的表皮视黄酯的损耗。因此，无需提供任何基质，仅通过诱导卵磷脂视黄醇酰基转移酶，视黄酸预防光诱导的类视黄醇损耗。
结论：在光诱导的类视黄醇损耗的这项研究中，视黄醛具有最佳的概况。
实施例2
角化细胞中类视黄醇诱导的视黄酯的调控。
在培养基中的角化细胞A431上进行该研究。事实上，在这些细胞中，没有测量到内源性类视黄醇。必须预先应用类视黄醇以测量细胞类视黄醇。通过HPLC测量类视黄醇。在培养基中，在溶解于1％乙醇中的各种试剂或试剂组合的存在下进行孵育，持续24至72h。
角化细胞中类视黄醇的生产示于下表中。这些是以pmol/mg蛋白质表示的平均值。
表1
OA：油酸；GG：双甘氨肽；OGG：双甘氨肽油酰胺；ROL-Pal：棕榈酸视黄酯；RAL：视黄醛。
该实验提供确立视黄醛诱导一系列视黄酯的可能性。双甘氨肽油酰胺显著增加了这些由视黄醛诱导的视黄酯，通过这种联系展现了真实的协同作用。棕榈酸视黄酯被吸收进入细胞中，然后被水解为视黄醇，之后所形成的视黄醇被部分酯化，最终产生比视黄醛少的细胞类视黄醇。
图2显示在孵育48h之后，由视黄醛和双甘氨肽油酰胺联合诱导的，对于调控角化细胞中诱导的视黄酯的协同作用。以用视黄醛处理的百分比表示值。
实施例3
视黄醛和双甘氨肽油酰胺和δ-生育酚-吡喃葡萄糖苷的组合对用UVA照射的人真皮成纤维细胞的作用。
该研究的目的是在照射成纤维细胞之前，评价这三种活性物质的保护性质。
在正常的人真皮成纤维细胞上进行该研究，所述细胞被接种于12孔板中，并在培养基中培养24小时。
为了探求保护作用，用含有或不含(对照)待测试产品的混合物的基质替换培养基，并将细胞孵育24小时。在预孵育结束时，用不含化合物的照射基质(milieu d'irradiation)替换基质，然后用UVA(20J/cm2)照射细胞或不照射(未照射对照)。在照射结束时，用测试基质(milieu d'essai)替换基质，并将细胞孵育48小时。所有的实验条件进行n＝3次。在实验结束时，提取RNA并通过RT–PCR测量64个基因的表达。
混合物包含：
‐1μM的视黄醛
‐1μM的双甘氨肽油酰胺
‐10μM的δ-生育酚-吡喃葡萄糖苷
UVA对人真皮成纤维细胞的照射明显抑制了许多参与细胞外基质组装的基因的表达，以及这种基质的某些组分的表达(图3)。平行地，在细胞周期的调节中，参与细胞外基质的降解的MMP1和MMP3标记物的明显的刺激被抑制。在64个经测试的基因中，25个受到UV的调节。这些结果是预料中的，并且提供了验证实验的可能性。
如图3所示，在三种活性物质的混合物的存在下，在13个基因中观察到实质性的保护作用，所述基因的表达被照射所改变。
出人意料地，这三种活性物质的混合物提供了观察基因中保护作用的可能性，所述基因涉及皮肤的弹性网状组织(如弹性蛋白、纤蛋白1(fibulin 1))，细胞和细胞外基质之间的相互作用(例如桩蛋白、多功能蛋白聚糖)，以及细胞核的保护(存活蛋白(survivin)、boréaline蛋白)。
图3提供了观察这三种活性物质的混合物恢复受到照射影响的基因的表达的可能性，也提供了揭示相比于对照条件4个基因的表达的增强的可能性(弹性蛋白、纤蛋白、赖氨酰氧化酶样蛋白2(lysyl oxidase-like 2)和巢蛋白1)。
因此，这三种活性物质的混合物不仅允许由照射所产生的改变的矫正，而且真皮的保护作用如此重要，尤其是对于涉及皮肤弹性的基因，在其中观察到皮肤弹性网状组织的真实重组，这三种活性物的混合物对于对抗皮肤老化是非常有效的。
实施例4
双甘氨肽油酰胺、视黄醛和δ-生育酚-吡喃葡萄糖苷的组合对用UVA照射的人皮肤的弹性网状组织的作用。
在人皮肤外植体上进行该研究，所述外植体被接种于6孔板中，并在培养基中培养48小时。用UVA(12J/cm2)照射皮肤或不照射(未照射对照)。为了探求保护作用，将含有或不含(安慰剂对照)0.1％的双甘氨肽油酰胺、0.05％的视黄醛和0.05％的δ-生育酚-吡喃葡萄糖苷的混合物的处方应用至皮肤的表面(10mg/cm2)直至照射结束。在孵育24小时之后，将相同量的保护处方再次应用至皮肤。将实验延长至24个小时，在实验结束时将皮肤冷冻并处理以通过免疫组织化学在共聚焦荧光显微镜下观察皮肤真皮的弹性网状组织。利用特异性抗体分析原纤蛋白和弹性蛋白的表达。
结果示于图4中，其涉及双甘氨肽油酰胺、视黄醛和δ-生育酚-吡喃葡萄糖苷混合物的局部应用，保护皮肤对抗由UVA照射诱导的弹性纤维的改变。事实上，UVA对皮肤外植体的照射强烈破坏了真皮中原纤蛋白和弹性蛋白的表达，并引起有许多破损的弹性纤维网状组织的实质性解体。安慰剂对照没有保护皮肤，并表现出与经UVA照射的皮肤相似的弹性网状组织。另一方面，含有三种活性物质的配方允许受到UVA影响的弹性纤维结构的修复，以及皮肤弹性的保护。经照射并用活性物质的混合物处理的皮肤的弹性网状组织的结构与未经照射的对照皮肤的结构完全相同。
双甘氨肽油酰胺、视黄醛和δ-生育酚-吡喃葡萄糖苷的组合提供了重组弹性皮肤组织的可能性，以及保护皮肤对抗由UVA产生的改变的可能性。因此，三种活性物质的混合物保护皮肤弹性，并有效地对抗皮肤的光老化。
整个结果证明了，视黄醛和双甘氨肽油酰胺的组合通过其协同效应将提供持续增加皮肤中维生素A的生理储备的可能性。视黄醛、双甘氨肽油酰胺和δ-生育酚-吡喃葡萄糖苷的组合将提供通过在真皮对众多目标的协同作用有效地对抗皮肤老化的可能性。
实施例5：霜剂
Claims (5)
1.一种组合物在制备用于增加皮肤中维生素A的生理储备的化妆品中的用途，其中所述组合物包含视黄醛和双甘氨肽油酰胺，以及至少一种化妆品上可接受的载体；所述组合物含有基于组合物总重量，以重量计0.01至1％的视黄醛，和以重量计0.0001至20％的双甘氨肽油酰胺。
2.根据权利要求1所述的用途，其中，所述组合物进一步包含δ-生育酚-吡喃葡萄糖苷。
3.根据权利要求2所述的用途，其中，所述组合物含有基于组合物总重量以重量计0.001至10％的δ-生育酚-吡喃葡萄糖苷。
4.根据权利要求3所述的用途，其中，所述组合物含有基于组合物总重量0.01至0.1％的视黄醛、0.1％的双甘氨肽油酰胺和0.05至0.1％的δ-生育酚-吡喃葡萄糖苷。
5.根据权利要求1至4中任一项所述的用途，其中，所述载体以旨在用于局部应用的形式出现。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1355036 | 2013-06-03 | ||
| FR1355036A FR3006191B1 (fr) | 2013-06-03 | 2013-06-03 | Compositions cosmetiques ou dermatologiques associant du retinaldehyde et de l'oleamide de glycylglycine, et leurs utilisations en cosmetique ou dermatologie |
| PCT/EP2014/061488 WO2014195315A1 (fr) | 2013-06-03 | 2014-06-03 | Compositions cosmetiques ou dermatologiques associant du retinaldehyde et de l'oleamide de glycylglycine, et leurs utilisations en cosmetique ou dermatologie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105377228A CN105377228A (zh) | 2016-03-02 |
| CN105377228B true CN105377228B (zh) | 2018-09-28 |
Family
ID=49237299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480039488.7A Active CN105377228B (zh) | 2013-06-03 | 2014-06-03 | 组合视黄醛和双甘氨肽油酰胺的化妆品或皮肤病学组合物及其化妆品或皮肤病学用途 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10213375B2 (zh) |
| EP (1) | EP3003263B1 (zh) |
| JP (1) | JP2016521697A (zh) |
| KR (1) | KR20160016814A (zh) |
| CN (1) | CN105377228B (zh) |
| AU (1) | AU2014276967B2 (zh) |
| BR (1) | BR112015030032A2 (zh) |
| CA (1) | CA2913885C (zh) |
| ES (1) | ES2710531T3 (zh) |
| FR (1) | FR3006191B1 (zh) |
| HK (1) | HK1217655A1 (zh) |
| MX (1) | MX364092B (zh) |
| PL (1) | PL3003263T3 (zh) |
| PT (1) | PT3003263T (zh) |
| RU (1) | RU2660359C2 (zh) |
| TR (1) | TR201901511T4 (zh) |
| WO (1) | WO2014195315A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11318077B2 (en) | 2017-09-29 | 2022-05-03 | Rodan & Fields, Llc | Retinaldehyde containing compositions and methods of use |
| CN111803396A (zh) * | 2020-06-30 | 2020-10-23 | 黑龙江省医院 | 一种基于视黄醛和双甘氨肽油酰胺的化妆品组合物及其制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1251989A (zh) * | 1997-02-25 | 2000-05-03 | 密执安州立大学董事会 | 防护和处理人皮肤经时性衰老的方法和组合物 |
| EP1061897B1 (fr) * | 1998-03-20 | 2002-09-25 | Pierre Fabre Dermo-Cosmetique | Oleamide de glycylglycine en dermo-cosmetologie |
| US6569906B1 (en) * | 1998-03-10 | 2003-05-27 | Pierre Fabre Dermo-Cosmetique | Composition containing a precursor capable of being hydrolysed by glucocerebrosidase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5984994A (ja) | 1982-11-06 | 1984-05-16 | 川研ファインケミカル株式会社 | ジペプチド化合物を含む液体洗浄剤組成物 |
| US4732690A (en) | 1985-03-18 | 1988-03-22 | Phillips Petroleum Company | Oil recovery composition |
| FR2681784B1 (fr) * | 1991-10-01 | 1995-06-09 | Fabre Pierre Cosmetique | Composition dermatologique et/ou cosmetologique contenant des retinouides et utilisation de nouveaux retinouides. |
| JPH0824562A (ja) * | 1994-07-11 | 1996-01-30 | Nagatoshi Suzuki | 放電プラズマを用いた脱臭装置 |
| JPH08245362A (ja) * | 1995-03-08 | 1996-09-24 | Seikagaku Kogyo Co Ltd | 紫外線損傷防御用外用剤 |
| FR2749511B1 (fr) * | 1996-06-07 | 1998-08-28 | Roc Sa | Methode cosmetique de traitement et de prevention des signes du vieillissement de la peau |
| RU2193400C1 (ru) * | 2001-12-26 | 2002-11-27 | Мерзленко Ольга Валерьевна | Способ профилактики и лечения болезней, связанных с недостаточностью витамина а |
| AU2003219269A1 (en) * | 2002-02-08 | 2003-09-02 | Societe D'extraction Des Principes Actifs (Vincience Sa) | Use of a hsp inducing compound to limit secondary effects of retinoids |
| JP2008222689A (ja) * | 2007-03-16 | 2008-09-25 | Kose Corp | 化粧料 |
| FR2945442B1 (fr) * | 2009-05-14 | 2012-08-03 | Fabre Pierre Dermo Cosmetique | Utilisation de delta-tocopheryl-glucide en tant qu'agent depigmentant. |
-
2013
- 2013-06-03 FR FR1355036A patent/FR3006191B1/fr active Active
-
2014
- 2014-06-03 BR BR112015030032A patent/BR112015030032A2/pt not_active Application Discontinuation
- 2014-06-03 JP JP2016517272A patent/JP2016521697A/ja not_active Ceased
- 2014-06-03 CN CN201480039488.7A patent/CN105377228B/zh active Active
- 2014-06-03 PL PL14727825T patent/PL3003263T3/pl unknown
- 2014-06-03 RU RU2015152964A patent/RU2660359C2/ru active
- 2014-06-03 EP EP14727825.3A patent/EP3003263B1/fr active Active
- 2014-06-03 CA CA2913885A patent/CA2913885C/fr active Active
- 2014-06-03 WO PCT/EP2014/061488 patent/WO2014195315A1/fr active Application Filing
- 2014-06-03 TR TR2019/01511T patent/TR201901511T4/tr unknown
- 2014-06-03 MX MX2015016553A patent/MX364092B/es active IP Right Grant
- 2014-06-03 AU AU2014276967A patent/AU2014276967B2/en not_active Ceased
- 2014-06-03 ES ES14727825T patent/ES2710531T3/es active Active
- 2014-06-03 US US14/895,429 patent/US10213375B2/en active Active
- 2014-06-03 KR KR1020157034065A patent/KR20160016814A/ko not_active Application Discontinuation
- 2014-06-03 PT PT14727825T patent/PT3003263T/pt unknown
-
2016
- 2016-05-20 HK HK16105770.7A patent/HK1217655A1/zh unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1251989A (zh) * | 1997-02-25 | 2000-05-03 | 密执安州立大学董事会 | 防护和处理人皮肤经时性衰老的方法和组合物 |
| US6569906B1 (en) * | 1998-03-10 | 2003-05-27 | Pierre Fabre Dermo-Cosmetique | Composition containing a precursor capable of being hydrolysed by glucocerebrosidase |
| EP1061897B1 (fr) * | 1998-03-20 | 2002-09-25 | Pierre Fabre Dermo-Cosmetique | Oleamide de glycylglycine en dermo-cosmetologie |
Non-Patent Citations (1)
| Title |
|---|
| Anti-aging properties of the association of "Retinaldehyde, Pretocopheryl glucopyranosyl, Glycylglycine oleamide";P Bogdanowicz等;《Journal of Investigative Dermatology》;20130531;第133卷(第2013增刊1期);第150页会议摘要879 * |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1217655A1 (zh) | 2017-01-20 |
| WO2014195315A1 (fr) | 2014-12-11 |
| FR3006191B1 (fr) | 2016-04-29 |
| EP3003263B1 (fr) | 2018-11-14 |
| JP2016521697A (ja) | 2016-07-25 |
| PL3003263T3 (pl) | 2019-05-31 |
| US10213375B2 (en) | 2019-02-26 |
| AU2014276967A1 (en) | 2016-01-21 |
| CA2913885C (fr) | 2021-06-01 |
| CA2913885A1 (fr) | 2014-12-11 |
| PT3003263T (pt) | 2019-02-21 |
| MX364092B (es) | 2019-04-12 |
| RU2660359C2 (ru) | 2018-07-05 |
| AU2014276967B2 (en) | 2019-07-11 |
| MX2015016553A (es) | 2016-08-03 |
| TR201901511T4 (tr) | 2019-02-21 |
| KR20160016814A (ko) | 2016-02-15 |
| US20160206542A1 (en) | 2016-07-21 |
| ES2710531T3 (es) | 2019-04-25 |
| BR112015030032A2 (pt) | 2017-07-25 |
| RU2015152964A (ru) | 2017-07-14 |
| EP3003263A1 (fr) | 2016-04-13 |
| CN105377228A (zh) | 2016-03-02 |
| FR3006191A1 (fr) | 2014-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11833242B2 (en) | Skin care formulations | |
| CA2749750C (en) | Skin care compositions and methods of use thereof | |
| CN105120834A (zh) | 抗氧化剂组合物及其使用方法 | |
| CN107638331A (zh) | 一种修护皮肤屏障且抵抗自由基的保湿乳液 | |
| KR20180103256A (ko) | 달맞이꽃 추출물을 포함하는 화장품용 조성물 | |
| Waqas et al. | Fabrication of Tamarindus indica seeds extract loaded-cream for photo-aged skin: Visioscan® studies | |
| CN111557892A (zh) | 含益生元的化妆品组合物 | |
| CN105377228B (zh) | 组合视黄醛和双甘氨肽油酰胺的化妆品或皮肤病学组合物及其化妆品或皮肤病学用途 | |
| TWI487703B (zh) | δ－生育基－碳水化合物作為脫色劑之用途 | |
| CH700735B1 (de) | Kosmetische Komposition für die Verjüngung des Erscheinungsbildes der Haut. | |
| JP2017206448A (ja) | 脱毛抑制剤 | |
| KR102548089B1 (ko) | 살리실산 및 비타민 c 유도체를 포함하는 화장료 조성물의 제조방법 및 이로부터 제조된 화장료 조성물 | |
| US20240293340A1 (en) | Putrescine topical barrier formulation | |
| KR101842693B1 (ko) | 나노리포좀으로 안정화된 갈로일 펩타이드를 유효성분으로 포함하는 화장료 조성물 | |
| KR20240046746A (ko) | 히알루론산의 조성물 및 단독 및 레티노이드와의 조합으로의 피부를 개선시키기 위한 용도 | |
| Shimoda | Food-derived materials improving skin cell health for smoother skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1217655 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |